Subclinical doxorubicin-induced cardiotoxicity update: role of neutrophils and endothelium

xlomafota13 shared this article with you from Inoreader Subclinical doxorubicin-induced cardiotoxicity update: role of neutrophils and endothelium Via American Journal of Cancer Research Am J Cancer Res. 2021 Sep 15;11(9):4070-4091. eCollection 2021. ABSTRACT Doxorubicin (DOX) is a highly effective chemotherapy agent that often causes cardiotoxicity. Despite a number of extensive studies, the risk for DOX cardiotoxicity remains unpredictable. The majority of the studies on DOX-induced cardiotoxicity have been focused on the effects on cardiomyocytes that lead to contractile dysfunction. The roles of systemic inflammation, endothelial injury and neutrophil recruitment, all induced by the DOX, are increasingly recognized as the mechanisms that trigger the development and progression of DOX-induced cardiomyopathy. This review explores recent data regarding the possible mechanisms and biomarkers of early subclinical DOX-associated cardiotoxicity. PMID:34659877 | PMC:PMC8493405 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.